If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
278
results.
Updated on
13/11/2026 [06:58:00]
Results 25 to 50 of 278
Absstract of: US20260358332A1
This invention relates to magnetic clusters comprising nanocrystals of iron oxide. The magnetic clusters comprise an aromatic carboxylic acid and/or the magnetic clusters are monodisperse. The magnetic clusters may be useful in biological assays and other applications. The invention also relates to processes for preparing such magnetic clusters and methods of using the magnetic clusters, as well kits comprising the magnetic clusters.
Absstract of: US20260355121A1
The current disclosure provides novel lipid nanoparticles comprising lung surfactants (Surf-LNPs) wherein said Surf-LNPs are useful for providing transfer of genetic material, i.e., nucleic acids, into cells and/or tissues of the lung or potentially other organs/tissues. Surf-LNPs comprise one or more biocompatible lipid components, one or more lung surfactants, and one or more nucleic acids encoding therapeutic agents, prophylactic agents or a combination thereof. The present disclosure further provides pharmaceutical compositions comprising said Surf-LNPs and their use in the treatment of lung disease. Said Surf-LNPs may also serve as vaccine compositions through the incorporation of nucleic acids therein which encode an immunogen or antigen of interest.
Absstract of: US20260355118A1
The present invention relates to compositions and methods for effective delivery of a therapeutic agent to a cardiomyocyte. The invention also relates to methods of use of the delivery methods of the invention for the treatment of diseases and disorders, including the treatment of cardiac diseases and disorders.
Absstract of: US20260355352A1
A nitrogen-branched non-linear PEGylated lipid containing a tertiary amine, which is represented by the Formula (1); wherein, B1 and B2 are linking bonds or alkylene groups; L1, L2, Ld and Lx are linking bonds or divalent linking groups L; R1 and R2 are C1-50 aliphatic hydrocarbon groups or C1-50 residues of aliphatic hydrocarbon derivative, each containing 0-10 heteroatoms; Ncore is a multivalent group of valence y+1 and contains a trivalent nitrogen-atom branching core connected to Ld; y is 2, 3, 4, 5, 6, 7, 8, 9, or ≥10; XPEG are polyethylene glycol components. Compared with linear PEGylated lipids, the nitrogen-branched PEGylated lipid herein can realize better surface modification of LNP. The present invention also provides a lipid pharmaceutical composition and its formulation containing the PEGylated lipid, which can enhance the targeting ability of drugs and improve the transfection efficiency of nucleic acid drugs.
Absstract of: AU2026257536A1
The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. Specifically, the disclosure provides a self-replicating RNA or a monocistronic self- replicating RNA comprising a nucleotide sequence encoding an antigen operably linked to a subgenomic promoter, wherein the antigen is from SARS-CoV-2, and wherein the antigen is a spike (S) protein or a nucleocapsid (N) protein. ct c t
Absstract of: AU2025433234A1
The present invention relates to an apparatus for softening a crystalline lens nucleus (100) in a cataract phacoemulsification treatment comprising an electric current pulse generator (11) to supply a pulse current to a handpiece (12), wherein the pulse current generates a pulsatile magnetic field, and to hydrodissect the lens nucleus with iron oxide nanoparticle solution to loosen the lens nucleus as well as to infiltrate the lens nucleus (14) with the iron oxide nanoparticles (13), characterised in that the needle tip (24) of the handpiece (12) conducts the generated pulsatile magnetic field to the lens nucleus which causes vibration of iron oxide nanoparticles which emanates a mechanical force to break interdigitating bonds between lens fibers, leading to a controlled softening and fragmenting of the lens nucleus, wherein the electric current pulse generator (11) is configured to produce pulse currents with adjustable voltage and frequency parameters, and the iron oxide nanoparticle solution (13) further comprises a superparamagnetic property functionalised with a biocompatible coating.
Absstract of: US20260355122A1
Disclosed is an ionizable lipid nanoparticle (LNP) composition having four lipid components: C12-200, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol, and (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol)-2000 (ammonium salt)) (DMPE-PEG). The LNP composition is useful for delivering RNA to the placenta, thus also providing methods of treating placenta-related disorders.
Absstract of: US20260355224A1
Disclosed herein are methods for managing disorders or conditions, or treating symptoms of disorders or conditions, comprising administering 5HT receptor agonists. The disorders may involve cognitive function and the methods of improving may comprise administering low doses of 5HT receptor agonists to subjects in need thereof. Improvement of the symptoms of a disorder involving cognitive function can be achieved where the disorders comprise mood, cognitive, anxiety, and depression disorders. Also disclosed herein are pharmaceutical compositions, formulations, and dosage forms of 5HT receptor agonists.
Absstract of: US20260355119A1
The invention provides intranasal formulation for pulmonary delivery of nanoparticles, compositions, uses, and manufacturing methods thereof. In one aspect, an intranasal formulation for intranasal or intrapulmonary administration includes a viscosity agent, an epithelial adherence agent, and a foaming agent. The viscosity agent may include carboxymethylcellulose, the epithelial adherence agent may include poly-lysine, and the foaming agent may include gelatin hydrolysate.
Absstract of: EP4837591A1
0001 The present invention relates to a nanomaterial for preventing tumor bone metastasis, a preparation method therefore and use thereof. The present invention discovers a spatiotemporal coupling interaction between tumor cells and osteoclasts, and provides a tumor-bone initial metastasis behavior-targeting strategy, which may accurately prevent tumor metastasis based on the source, and may avoid drug resistance and biochemical resistance. Based on this, the present invention designs a nanomaterial for physical killing targeting tumor-osteoclast conjugates, and the nanomaterial is a bone-targeting group-modified nanovesicle encapsulating a carbonate compound and a phosphate compound. The nanomaterial can be effectively enriched in bone tissue; when the tumor cells are activated, an acid secretion function of tumor-related osteoclasts in the tumor-osteoclast conjugates in close contact triggers the carbonate compound to generate a carbon dioxide gas, and promotes the phosphate compound to release to form calcium phosphate crystals with a calcium ion, so as to kill nearby tumor cells, thereby achieving a specific very-early tumor metastasis inhibition effect.
Absstract of: EP4837568A1
The present invention relates to a surface-modified albumin nanoplatform, a method for preparing the same, and a composition for diagnosing or treating a disease using the same. The surface-modified albumin nanoplatform according to the present invention can reduce uptake by the reticuloendothelial system even when an excessive amount of click functional groups and various transmitters are conjugated to albumin, by deactivating the click-reactive functional groups on the surface of the albumin to which a transmitter is not conjugated, and accordingly, the in vivo half-life is greatly increased, so that a target molecule or active material can be effectively delivered to a target tissue or cell, thereby achieving excellent therapeutic and diagnostic effects.
Absstract of: WO2025146681A1
The present invention relates to pro-nano-emulsion compositions comprising at least one type of Omega 3 fatty acid capable of converting to nano-emulsion composition having average droplet size of below Ip, typically below 0.5p, and use thereof, particularly as dietary supplement, for preferential delivery of the Omega 3 fatty acid to heart and/or liver tissue of a subject consuming the composition, thereby maintaining normal cardiovascular/hepatic function and/or improving cardiovascular/hepatic disease or disorders.
Absstract of: WO2025147516A1
The present invention provides a lipid nanoparticle comprising an entity that contains one or multiple sialic acid (SA) moieties, the entity is preferably a ganglioside, a ganglioside derivative, a ganglioside mimetic, or a combination thereof. The lipid nanoparticle of the present invention can effectively present SA moieties on the surface to bind Siglecs and complement factors to, inter alia, mitigate inflammation. The present invention also provides methods of using said lipid nanoparticle compositions described herein for pharmaceutical applications. For example, the lipid nanoparticles provided herein are useful for treating inflammatory and autoimmune diseases.
Absstract of: WO2025147545A1
The present disclosure relates to compositions comprising lipid nanoparticles for delivering nucleic acid molecules into cells. Also included are methods for producing and using such compositions.
Absstract of: EP4837902A1
The present application discloses a compound with a structural formula shown as formula (I), and a salt and an isomer thereof. The present application further discloses a nanoparticle composition including the compound, or the salt or the isomer thereof. Nanoparticles of the present application may efficiently deliver a drug or a vaccine into a cell, to exert a therapeutic or prophylactic effect of the drug or the vaccine.
Absstract of: AU2025205865A1
A composition for genetic editing of a hydroxyacid oxidase 1 (HAO1) gene, comprising: (a) a messenger RNA (mRNA) encoding a Cas12i2 polypeptide, (b) a guide RNA (gRNA) targeting the HAO1 gene; and (c) lipid excipients, which optionally form lipid nanoparticles. Also provided herein are methods for genetic modification of the HAO1 gene in host cells with the composition provided herein.
Absstract of: EP4837897A1
0001 The present disclosure relates to a PEG lipid and the use thereof. The PEG lipid can be used for preparing a lipid nanoparticle that delivers an active ingredient. The present disclosure further relates to a pharmaceutical composition and a lipid nanoparticle comprising the PEG lipid, as well as the use thereof in preparing a pharmaceutical.
Absstract of: EP4837592A1
0001 The present invention discloses a lipid nanoparticle (LNP) and its application, comprising cationic ionisable lipids, auxiliary lipids, ligand-modified PEGylated lipids, and cholesterol. The auxiliary lipids and ligand-modified PEGylated lipids target receptors on the surface of liver sinusoidal endothelial cells (LSECs). The LNPs enhance LSEC-specific uptake through a targeted design involving the lipid-specific interaction pathway.
Absstract of: EP4837915A1
The present invention is directed to silicon containing ionizable lipids, lipid nanoparticles (LNPs) comprising at least one ionizable lipid according to the invention, pharmaceutical compositions comprising a lipid nanoparticle according to the inventio and a pharmaceutically acceptable carrier as well as their pharmaceutical use.
Absstract of: EP4837917A2
0001 The present disclosure provides a capping analog for self-replicating mRNA and uses thereof, wherein the capping analog for self-replicating mRNA is capable of enhancing the stability and/or translation efficiency of the self-replicating mRNA.
Absstract of: WO2025147528A1
The present invention is based on the surprising discovery that a lipid nanoparticle (LNP) bearing sialic acid residues on the surface can withstand nebulization and maintain its integrity. The invention provides an LNP composition comprising a lipid bearing, or substituted by, a sialic acid (SA) residue such as a ganglioside, a ganglioside derivative, a mimetic, a SA-bearing entity or a combination thereof. The lipid nanoparticles described herein can incorporate nucleic acid molecules, or cargos, withstanding nebulization, and delivering the cargos to the lung via a nebulization-mediated delivery. The present invention also provides methods of using the LNP compositions described herein for pharmaceutical applications. For example, the LNPs provided herein are useful for the treatment of various pulmonary diseases. The LNPs provided herein are also useful for prophylactic applications including vaccines for infectious diseases, allergies, autoimmune diseases and cancer.
Absstract of: WO2025210520A1
The present disclosure provides lipid nanoparticles that are particularly beneficial in inducing an immune response in a subject, particularly by stimulating production of antibodies by the subject. The lipid nanoparticles can include one or more of a low conjugated lipid concentration, a neutral phospholipid, and a concentration of an ionizable lipid and/or sterol that satisfy certain thresholds dependent on the conjugated lipid concentration. The disclosure also provides vaccines, other pharmaceutical compositions, and methods including the provided lipid nanoparticles.
Absstract of: GB2639579A
An antimicrobial composition comprising an antimicrobial compound and a population of metal nanoparticles is provided. The antimicrobial compound is preferably an antibiotic. The metal nanoparticle may comprise silver and/or copper and may also comprise a polymer coating such as poly(N-vinylpyrrolidone). The antimicrobial composition wherein the population of silver nanoparticles is formed by (a) mixing a first aqueous alkaline solution with an aqueous polymer solution to form an aqueous polymer solution; and (b) mixing the aqueous alkaline polymer solution with an aqueous solution of a metal salt to form a solution of polymer-coated metal nanoparticles is provided. A coating or treatment for a surface or substrate comprising the antimicrobial composition is provided. A medical device comprising the coating or treatment is provided. The medical device may be a wound care dressing or a bandage. A silver nanoparticle coated with poly(N-vinylpyrrolidone) is exemplified. Combinations of the PVP-coated silver nanoparticles (AgNP) and various antibiotics were tested. Compositions comprising silver nanoparticles and aminoglycosides, such as kanamycin and gentamicin, were particularly effective. A combination of silver nanoparticles and ebselen was also particularly effective against E. coli and S. aureus.
Absstract of: WO2025160324A2
Provided herein are methods of inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a cell or a population of cells in a subject, methods of expressing a polypeptide of interest from a target genomic locus in a cell or a population of cells in a subject, methods of treating an enzyme deficiency in a subject in need thereof, and methods of preventing or reducing the onset of a sign or symptom of an enzyme deficiency in a subject in need thereof. Some methods, such as when a subject has preexisting against an immunogen to be administered, use plasma cell depleting agents or combinations comprising plasma cell depleting agents to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of the nucleic acid construct without overshooting. Other methods, such as when a subject has no preexisting immunity against an immunogen to be administered, use B cell depleting agents (e.g., anti-CD20xCD3 antibody or functional fragment thereof) to mitigate immune response and facilitate redosing of nucleic acid constructs encoding a polypeptide of interest and nuclease agents targeting a target genomic locus to achieve, for example, a step-wise increase in expression of a polypeptide of interest in a subject following insertion of
Nº publicación: CN123063463A 10/11/2026
Applicant:
中央民族大学
Absstract of: CN123063463A
本发明提供了用于治疗ADSL基因缺陷相关疾病的腺相关病毒及其应用。本发明提供了包含5' ITR，启动子，ADSL基因编码序列，转录调控元件，polyA，3' ITR的质粒载体，以及由该质粒和包装质粒、辅助质粒包装而成的重组腺相关病毒。本发明通过实验证明所述重组腺相关病毒可以有效治疗ADSL基因缺陷相关疾病，具有广阔的应用前景。
BOPI
Electronic site
